Department of Laboratory Medicine, Karolinska Institutet at Karolinska University Hospital Huddinge, Stockholm, Sweden.
Vaccine. 2013 Apr 26;31(18):2231-7. doi: 10.1016/j.vaccine.2013.03.002. Epub 2013 Mar 14.
The relevance of CD4+T-cells, viral load and age in the immunological response to influenza infection and vaccination in HIV-1 infected individuals has previously been pointed out. Our study aimed at assessing, in the setting of 2009 A(H1N1)pdm09 influenza vaccination, whether quantification of activation-induced deaminase (AID) expression in blood B-cells may provide additional indications for predicting antibody response to vaccination in HIV-1 infected patients with similar CD4+T-cell counts and age. Forty-seven healthy controls, 37 ART-treated and 17 treatment-naïve HIV-1 infected patients were enrolled in the study. Blood was collected prior to A(H1N1)pdm09 vaccination and at 1, 3 and 6 months after vaccination. Antibody titers to A(H1N1)pdm09 vaccine were measured by hemagglutination inhibition (HI) assay while the mRNA expression levels of AID were measured by quantitative real time PCR. Upon B-cell activation in vitro, AID increase correlated to antibody response to the A(H1N1)pdm09 vaccine at 1 month after vaccination in all individuals. In addition, the maximum expression levels of AID were significantly higher in those individuals who still carried protective levels of A(H1N1)pdm09 antibodies after 6 months from vaccination. No correlation was found between CD4+T-cell counts or age at vaccination or HIV-1 viral load and levels of A(H1N1)pdm09 antibodies. Assessing AID expression before vaccination may be an additional useful tool for defining a vaccination strategy in immune-compromised individuals at risk of immunization failure.
先前已经指出,CD4+T 细胞、病毒载量和年龄与 HIV-1 感染者对流感感染和疫苗接种的免疫反应有关。我们的研究旨在评估 2009 年 A(H1N1)pdm09 流感疫苗接种时,血液 B 细胞中激活诱导脱氨酶(AID)表达的定量是否可以为预测 HIV-1 感染患者的抗体反应提供额外的依据,这些患者的 CD4+T 细胞计数和年龄相似。本研究纳入了 47 名健康对照者、37 名接受 ART 治疗的 HIV-1 感染者和 17 名未接受治疗的 HIV-1 感染者。在接种 A(H1N1)pdm09 疫苗前以及接种后 1、3 和 6 个月采集血液。通过血凝抑制(HI)测定法测量对 A(H1N1)pdm09 疫苗的抗体滴度,通过实时定量 PCR 测量 AID 的 mRNA 表达水平。在体外 B 细胞激活后,所有个体在接种后 1 个月时,AID 的增加与对 A(H1N1)pdm09 疫苗的抗体反应相关。此外,在接种后 6 个月仍保持 A(H1N1)pdm09 抗体保护水平的个体中,AID 的最大表达水平明显更高。在接种时 CD4+T 细胞计数或年龄或 HIV-1 病毒载量与 A(H1N1)pdm09 抗体水平之间未发现相关性。在接种前评估 AID 表达可能是为免疫功能低下的个体定义免疫失败风险的疫苗接种策略的另一个有用工具。